1. Main purpose Objective to study the tolerance and safety of single and multiple
administration of repeated 28-day cycles of AL8326 in patients with advanced solid
tumor, observe the dose limiting toxicity (DLT) and maximum tolerated dose (MTD).
2. Secondary purpose 1) Preliminary analysis of the pharmacokinetic characteristics and
efficacy of repeated 28-day cycles of AL8326 tablets in patients with advanced solid
tumors; 2) According to the results of phase I tolerance test and pharmacokinetics,
appropriate dosage and regimen were recommended for phase II clinical trial;